Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study

BACKGROUND: The objective of this study was to carry out a cost-effectiveness analysis of dapagliflozin, as an add-on therapy to standard of care (SoC), for the treatment of type 2 diabetes mellitus (T2DM) in Spain, based on the results of the DECLARE-TIMI 58 trial. METHODS: A discrete event simulat...

Descripción completa

Detalles Bibliográficos
Autores principales: Escobar, Carlos, Morales, Cristóbal, Capel, Margarita, Simón, Susana, Pérez-Alcántara, Ferran, Pomares, Elisenda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8851809/
https://www.ncbi.nlm.nih.gov/pubmed/35177053
http://dx.doi.org/10.1186/s12913-022-07567-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8851809/
https://www.ncbi.nlm.nih.gov/pubmed/35177053
http://dx.doi.org/10.1186/s12913-022-07567-5

Ejemplares similares